|
1
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hermann PC, Bhaskar S, Cioffi M and
Heeschen C: Cancer stem cells in solid tumors. Semin Cancer Biol.
20:77–84. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirose Y, Katayama M, Mirzoeva OK, Berger
MS and Pieper RO: Akt activation suppresses Chk2-mediated,
methylating agent-induced G2 arrest and protects from
temozolomide-induced mitotic catastrophe and cellular senescence.
Cancer Res. 65:4861–4869. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molina JR, Hayashi Y, Stephens C and
Georgescu MM: Invasive glioblastoma cells acquire stemness and
increased Akt activation. Neoplasia. 12:453–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eyler CE, Foo WC, LaFiura KM, McLendon RE,
Hjelmeland AB and Rich JN: Brain cancer stem cells display
preferential sensitivity to Akt inhibition. Stem Cells.
26:3027–3036. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Caporali S, Levati L, Starace G, Ragone G,
Bonmassar E, Alvino E and D'Atri S: AKT is activated in an
ataxia-telangiectasia and Rad3-related-dependent manner in response
to temozolomide and confers protection against drug-induced cell
growth inhibition. Mol Pharmacol. 74:173–183. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Salvo M, Maresca G, D'Agnano I,
Marchese R, Stigliano A, Gagliassi R, Brunetti E, Raza GH, De Paula
U and Bucci B: Temozolomide induced c-Myc-mediated apoptosis via
Akt signalling in MGMT expressing glioblastoma cells. Int J Radiat
Biol. 87:518–533. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gallia GL, Tyler BM, Hann CL, Siu IM,
Giranda VL, Vescovi AL, Brem H and Riggins GJ: Inhibition of Akt
inhibits growth of glioblastoma and glioblastoma stem-like cells.
Mol Cancer Ther. 8:386–393. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen L, Han L, Shi Z, Zhang K, Liu Y,
Zheng Y, Jiang T, Pu P, Jiang C and Kang C: LY294002 enhances
cytotoxicity of temozolomide in glioma by down-regulation of the
PI3K/Akt pathway. Mol Med Rep. 5:575–579. 2012.PubMed/NCBI
|
|
12
|
Zhang WB, Wang Z, Shu F, Jin YH, Liu HY,
Wang QJ and Yang Y: Activation of AMP-activated protein kinase by
temozolomide contributes to apoptosis in glioblastoma cells via p53
activation and mTORC1 inhibition. J Biol Chem. 285:40461–40471.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin. Diabetes Care.
29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gritti M, Wurth R, Angelini M, Barbieri F,
Peretti M, Pizzi E, Pattarozzi A, Carra E, Sirito R, Daga A, et al:
Metformin repositioning as antitumoral agent: Selective
antiproliferative effects in human glioblastoma stem cells, via
inhibition of CLIC1-mediated ion current. Oncotarget.
5:11252–11268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kast RE, Karpel-Massler G and Halatsch ME:
Can the therapeutic effects of temozolomide be potentiated by
stimulating AMP-activated protein kinase with olanzepine and
metformin? Br J Pharmacol. 164:1393–1396. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sato A, Sunayama J, Okada M, Watanabe E,
Seino S, Shibuya K, Suzuki K, Narita Y, Shibui S, Kayama T and
Kitanaka C: Glioma-initiating cell elimination by metformin
activation of FOXO3 via AMPK. Stem cells Transl Med. 1:811–824.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wurth R, Pattarozzi A, Gatti M, Bajetto A,
Corsaro A, Parodi A, Sirito R, Massollo M, Marini C, Zona G, et al:
Metformin selectively affects human glioblastoma tumor-initiating
cell viability: A role for metformin-induced inhibition of Akt.
Cell Cycle. 12:145–156. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bolen S, Feldman L, Vassy J, Wilson L, Yeh
HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, et al:
Systematic review: Comparative effectiveness and safety of oral
medications for type 2 diabetes mellitus. Ann Intern Med.
147:386–399. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zakikhani M, Blouin MJ, Piura E and Pollak
MN: Metformin and rapamycin have distinct effects on the AKT
pathway and proliferation in breast cancer cells. Breast Cancer
Res. 123:271–279. 2010. View Article : Google Scholar
|
|
22
|
Rattan R, Ali Fehmi R and Munkarah A:
Metformin: An emerging new therapeutic option for targeting cancer
stem cells and metastasis. J Oncol. 2012:9281272012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Quinn BJ, Kitagawa H, Memmott RM, Gills JJ
and Dennis PA: Repositioning metformin for cancer prevention and
treatment. Trends Endocrinol Metab. 24:469–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Soritau O, Tomuleasa C, Aldea M, Petrushev
B, Susman S, Gheban D, Ioani H, Cosis A, Brie I, Irimie A, et al:
Metformin plus temozolomide-based chemotherapy as adjuvant
treatment for WHO grade III and IV malignant gliomas. J BUON.
16:282–289. 2011.PubMed/NCBI
|
|
25
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
27
|
Sachlos E, Risueño RM, Laronde S,
Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn
A, Graham M, et al: Identification of drugs including a dopamine
receptor antagonist that selectively target cancer stem cells.
Cell. 149:1284–1297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Janjetovic K, Vucicevic L, Misirkic M,
Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S,
Bumbasirevic V, Trajkovic V, et al: Metformin reduces
cisplatin-mediated apoptotic death of cancer cells through
AMPK-independent activation of Akt. Eur J Pharmacol. 651:41–50.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu X, Chhipa RR, Pooya S, Wortman M,
Yachyshin S, Chow LM, Kumar A, Zhou X, Sun Y, Quinn B, et al:
Discrete mechanisms of mTOR and cell cycle regulation by AMPK
agonists independent of AMPK. Proc Natl Acad Sci USA.
111:E435–E444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meier FE, Lasithiotakis K, Schittek B,
Sinnberg T and Garbe C: Temozolomide combined with the PI3K
inhibitor LY294002 or the mTOR inhibitor rapamycin inhibits
melanoma cell growth, survival and invasion. J Clin Oncol. 25(Suppl
18): 85592007.
|
|
32
|
Kandel ES, Skeen J, Majewski N, Di
Cristofano A, Pandolfi PP, Feliciano CS, Gartel A and Hay N:
Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle
checkpoint induced by DNA damage. Mol Cellular Biol. 22:7831–7841.
2002. View Article : Google Scholar
|
